SLC5A2 and diabetes mellitus: Both the American Diabetes Association and Kidney Disease: Improving Global Outcomes recommend a SGLT2 inhibitor as first-line pharmacotherapy in diabetes and CKD with estimated glomerular filtration rate ≥20 mL/min/1.73 m2, in addition to the long-established RAS blocker [4].